NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

Trinity Biotech plc (TRIB) Stock Analysis

Trinity Biotech plc (TRIB) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

TRIB

$9.41

−$0.19 (−1.98%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TRIB with… →

TRIB Key Statistics

As of Sep 4, 2026
Trading
Open
$9.50
Previous Close
$9.60
Day's Range
9.24–9.84
52-Week Range
7.94–52.50
Volume
11.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.97
Valuation
Market Cap
$7.65M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.30
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.17
EPS (ttm)Profit attributable to each share over the last twelve months.
−60.00
Financials (FY)
Revenue (FY)
$43.79M−28.87%
Net Income (FY)
−$37.38M
Profit marginThe share of revenue left as profit after all costs and taxes.
−85.36%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
813.13K
1-Year Return
+718.26%
Dividend and dates
Avg Volume
58.71K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TRIB Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+1091.14%
2025−10.23%
2024−59.07%
2023−56.57%
2022−30.77%
2021−62.47%
2020+269.90%
2019−55.02%
2018−55.10%
2017−26.30%
2016 (partial year)−46.56%

As of September 4, 2026.

TRIB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$43.79M−$37.38M−85.4%
2024$61.56M−$31.79M−51.6%
2023$56.83M−$24.02M−42.3%
2022$62.52M−$41.01M−65.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$43.79M$16.89M−$11.42M−$37.38M−85.4%
2024$61.56M$21.44M−$13.70M−$31.79M−51.6%
2023$56.83M$19.45M−$15.94M−$24.02M−42.3%
2022$62.52M$17.27M−$13.51M−$41.01M−65.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TRIB Valuation vs Medical Devices Median

Median of 151 stocks
MetricTRIBMedical Devices medianvs median
P/S ratio0.172.980.1x the median
Profit margin−85.36%−1.69%83.7 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Trinity Biotech plc (TRIB) at $7.65M. The company sits in the Healthcare sector, in the Medical Devices industry. The company reports 287 employees.

The most recent close on file for TRIB is $9.41, dated September 4, 2026. That is −$0.19 (−1.98%) against the previous close. Over the past 52 weeks the price has ranged from $7.94 to $52.50. The latest close sits 18.51% above that 52-week low.

Financial Health

In fiscal 2025, Trinity Biotech plc reported revenue of $43.79M. That is −28.87% against the prior fiscal year, when revenue was $61.56M. The same year closed with a net loss of $37.38M. The reported profit margin is −85.36%. That is 83.7 percentage points below the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to −60.

Across the 4 fiscal years on file, revenue moves from $62.52M in 2022 to $43.79M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.3. Measured against sales, the shares trade at 0.17 times revenue. On price-to-sales that is 0.1 times the Medical Devices median of 2.98. 151 Medical Devices companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.97. Daily returns over the trailing 10 years annualize to a volatility of 766.14%. The trailing one-year price return is +718.26%. Measured over 10 years, that is −17.80% a year compounded.

Growth & Income

No dividend is on file for TRIB.

Across the complete calendar years on file, 2020 returned +269.90% and 2021 returned −62.47%. Of the 9 complete calendar years on file, 1 finished higher. So far in 2026 the price is +1,091.14%.

Peer Comparison

Trinity Biotech plc (TRIB) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Trinity Biotech plc TRIB $7.65M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Trinity Biotech plc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Trinity Biotech plc

Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. In addition, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. It has a collaboration agreement with a bioinformatics company to conduct analysis on clinical trial data for EpiCapture, a molecular diagnostics company for developing a non invasive urine based prognostic test for progression to aggressive prostate cancer. It has a strategic collaboration agreement with Echelon Data Centres to develop advanced liquid cooling solutions for AI infrastructure. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Visit website →